We are live on
!
Find out more
Fayez Sarofim & Co Portfolio holdings
AUM
$39.1B
1-Year Est. Return
15.14%
This Fund
S&P 500
This Quarter
Est. Return
-1.71%
1 Year Est. Return
+15.14%
3 Year Est. Return
+57.14%
5 Year Est. Return
+86.44%
10 Year Est. Return
+281.86%
AUM
$39.1B
AUM Growth
-$2.58B
(-6.2%)
Cap. Flow
-$777M
Cap. Flow
% of AUM
-1.99%
Top 10 Holdings %
Top 10 Hldgs %
48.1%
Holding
304
New
7
Increased
61
Reduced
122
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Blackstone
BX
|
+$189M |
| 2 |
NVIDIA
NVDA
|
+$148M |
| 3 |
Meta Platforms (Facebook)
META
|
+$51.9M |
| 4 |
Spotify
SPOT
|
+$39.2M |
| 5 |
AbbVie
ABBV
|
+$38.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$391M |
| 2 |
Apple
AAPL
|
+$135M |
| 3 |
Broadridge
BR
|
+$99.4M |
| 4 |
CoStar Group
CSGP
|
+$97.2M |
| 5 |
Zoetis
ZTS
|
+$48.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.98% |
| 2 | Financials | 18.32% |
| 3 | Consumer Staples | 10.72% |
| 4 | Energy | 9.97% |
| 5 | Communication Services | 9.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Abbott
ABT
$175B
| $440M | 1.12% |
4,282,135
-198,385
| -4% | -$22.4M |
|
27
UnitedHealth
UNH
$387B
| $434M | 1.11% |
1,603,772
+49,627
| +3% | +$14.8M |
|
28
Procter & Gamble
PG
$349B
| $416M | 1.06% |
2,877,535
-170,115
| -6% | -$25.8M |
|
29
T. Rowe Price
TROW
$25.1B
| $400M | 1.02% |
4,435,361
-300,925
| -6% | -$29.2M |
|
30
Eli Lilly
LLY
$1.05T
| $389M | 1% |
423,173
-1,223
| -0.3% | -$1.24M |
|
|
31
Blackstone
BX
$155B
| $366M | 0.94% |
3,179,857
+1,449,415
| +84% | +$189M |
|
32
Canadian Pacific Kansas City
CP
$83.2B
| $363M | 0.93% |
4,621,108
-14,668
| -0.3% | -$1.16M |
|
33
CME Group
CME
$88.5B
| $361M | 0.92% |
1,222,003
-28,464
| -2% | -$8.45M |
|
34
Chubb
CB
$137B
| $348M | 0.89% |
1,068,988
-2,442
| -0.2% | -$783K |
|
35
Berkshire Hathaway Class B
BRK.B
$1.06T
| $328M | 0.84% |
684,439
-6,003
| -0.9% | -$2.95M |
|
36
Intercontinental Exchange
ICE
$79B
| $305M | 0.78% |
1,942,169
-88,337
| -4% | -$14.4M |
|
37
Altria Group
MO
$124B
| $290M | 0.74% |
4,394,936
-68,676
| -2% | -$4.42M |
|
38
Marriott International
MAR
$96.6B
| $281M | 0.72% |
859,756
-88,428
| -9% | -$29.1M |
|
39
Automatic Data Processing
ADP
$102B
| $278M | 0.71% |
1,369,729
-2,032
| -0.1% | -$466K |
|
40
Morgan Stanley
MS
$339B
| $269M | 0.69% |
1,635,037
-33,894
| -2% | -$5.87M |
|
|
41
Berkshire Hathaway Class A
BRK.A
$1.06T
| $262M | 0.67% |
365
-3
| -0.8% | -$2.21M |
|
42
Deere & Co
DE
$161B
| $256M | 0.65% |
453,998
-4,554
| -1% | -$2.57M |
|
43
EOG Resources
EOG
$74.5B
| $250M | 0.64% |
1,728,678
-12,323
| -0.7% | -$1.5M |
|
44
Home Depot
HD
$338B
| $250M | 0.64% |
759,860
+16,650
| +2% | +$6.07M |
|
|
BNY
45
Bank of New York Mellon
BNY
$108B
| $222M | 0.57% |
1,873,899
-45,750
| -2% | -$5.44M |
|
46
Merck
MRK
$315B
| $205M | 0.52% |
1,700,379
-39,510
| -2% | -$4.56M |
|
47
Sherwin-Williams
SHW
$81.7B
| $202M | 0.52% |
629,232
-28,088
| -4% | -$9.67M |
|
48
ServiceNow
NOW
$106B
| $198M | 0.51% |
1,893,935
+17,426
| +0.9% | +$2.05M |
|
49
Linde
LIN
$237B
| $196M | 0.5% |
395,303
-5,538
| -1% | -$2.61M |
|
50
Walmart Inc
WMT
$909B
| $195M | 0.5% |
1,566,842
-23,330
| -1% | -$2.86M |
|
Similar funds
HF
Fayez Sarofim & Co's Q1 2026 Portfolio in Review
As of Q1 2026, Fayez Sarofim & Co held 304 positions worth $39.1B, down 6.2% from $41.7B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Fayez Sarofim & Co's Q1 2026 filing shows 7 new, 61 increased, 122 reduced and 10 closed positions. Its largest new stake was Versant Media Group: 15,524 shares worth $575K. The largest sale was AstraZeneca, an estimated $391M.
By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 32% a quarter earlier, followed by Financials and Consumer Staples.
- Fayez Sarofim & Co's largest Q1 2026 buy was Versant Media Group: 15,524 shares worth $575K.
- Fayez Sarofim & Co added most to Blackstone in Q1 2026, an estimated $189M increase.
- Fayez Sarofim & Co's biggest Q1 2026 reduction was Apple, cutting an estimated $135M.
- Fayez Sarofim & Co fully exited AstraZeneca in Q1 2026, selling an estimated $391M.
- Fayez Sarofim & Co's ten largest holdings make up 48% of its $39.1B portfolio in Q1 2026.
- Fayez Sarofim & Co opened 7 new positions and closed 10 in Q1 2026.
- Fayez Sarofim & Co's portfolio value fell 6.2% quarter-over-quarter to $39.1B.
Based on Fayez Sarofim & Co's 13F filing for Q1 2026, filed 15 May 2026.